Prostate laser surgery forum sydney,enlarged prostate catheter kit,best prostate health complex,symptoms of inflammation of prostate gland 3d - Videos Download

08.11.2015
This topic has 2 replies You must be a registered member and logged in to view the replies in this topic. Mr Iqbal Shergill, Consultant Urological Surgeon is delighted to warmly welcome you to his website! This website aims to inform all patients and healthcare professionals about the practice of Urology, by Mr Shergill, in Wrexham, North Wales, as well as Chester, Cheshire and North West England.
Urology refers to the medical and surgical treatment of diseases of the urinary tract, including those of the kidney, ureter, bladder and prostate. Importantly, Mr Shergill recognises the value and importance of effective multi-disciplinary team-working in the overall management of all patients and has published editorial on this Multidisciplinary (MDT) Teamworking.
Mr Shergill and his team, aim to provide a professional and personalised approach to patient care, with individualised urological treatment. A new, minimally invasive surgical procedure to treat an enlarged prostate, or Benign Prostatic Hyperplasia (BPH), has been successfully completed for the first time by Mr Shergill. For patients with prostate cancer, Mr Shergill is now offering insertion of fiducial gold seeds (Simon put in images below) prior to radiotherapy treatment. Mr Shergill has recently been elected to the British Association of Urological Surgeons (BAUS) Section of Academic Urology Executive Committee.
Mr Shergill is the Principal Investigator in several national and international multi-centre clinical research trials in urology. INDEX Trial - This is a National Cancer Research Network (NCRN) multi-centre prospective trial evaluating Focal Therapy using High Intensity Focused Ultrasound for the treatment of localised prostate cancer. PROMIS Trial - This is a Medical Research Council (MRC PR11) multi-centre trial investigating the use of multi-parametric Magnetic Resonance Imaging (MP-MRI) as a tool in the diagnosis of prostate cancer.
SURTIME Trial - This is an EORTC (European Organisation for Research and Treatment of Cancer) randomized Phase III trial comparing immediate versus deferred nephrectomy in patients with synchronous metastatic renal cell carcinoma.
COMPARE Trial - This clinical trial is evaluating patient preferences for the treatment of localized prostate cancer (COMparing treatment options for ProstAte cancer).
The European Board of Urology is a section office of the European Union of Medical Specialists (UEMS) and its objectives are to study, promote and harmonise urological training in Europe. The FEBU examination offers a systematic assessment for the recognition of quality and is recognised internationally as a Mark of Excellence in Urology. An inaugural meeting of patients with Cystinuria and clinicians diagnosing, treating and managing Cystine Kidney Stones in North Wales and Cheshire was held recently. Mr Shergill, and his team at the Spire Yale hospital, are the first clinical team in Wales to offer HIFU treatment for prostate cancer patients. Recently, as reported on Sky News, BBC News and the national newspapers, research has shown that prostate cancer can now be treated effectively with HIFU, importantly, with very minimal incontinence and impotence rates. Mr Shergill, and his team at the Spire Yale are now offering Prostate Mapping (Transperineal Template biopsies of the prostate). Due to the more accurate and more complete sampling of the gland a cancer detection rate of 78% is reported. In their efforts to establish world class stone and endourological services at Wrexham Maelor Hospital, Mr Shergill and his colleagues have recently obtained a state-of-the art Laser system, for the treatment of all forms of kidney stones.


The Laser system has been purchased from a generous donation by Maelor Voluntary Services and it is widely anticipated that a wide range of benefits for patients will be achieved, including: Improved overall quality of treatment for patients, reduced need for multiple treatments, reduced need for multiple admissions, patients not requiring referral to hospitals outside Wrexham, virtually all procedures can be performed as Day Cases, reduced rates of postoperative discomfort, quicker return to work and normal activities, fewer complications (particularly useful in the large group of Jehovah's Witness patients and elderly patients on blood thinning medications who are increasingly developing kidney stones) and finally higher patient satisfaction rates, as patients receive modern 21st Century urological surgery. Indeed, in addition to providing 21st Century surgical treatment of urological stone disease, other urological diseases, including bladder cancer and some forms of early kidney cancer, can be treated with this Laser system. Mr Shergill has published two articles on kidney stones in the local Daily Post newspaper View here for Article on Kidney Stones Assessment and View here for Article on Laser treatment.
One of Mr Shergill's Core Surgical Trainees has received the "Best Welsh Core Surgical Trainee Award 2011" for his surgical training portfolio, whilst at Wrexham Maelor Hospital urology department. In this test, a urine sample is collected following an examination of the prostate for the determination of the PCA3 Score. Mr Shergill and his dedicated multi disciplinary team at the Spire Yale Hospital, Wrexham, have introduced an innovative new Men's Health Check clinic (View Men's Health Clinic Flyer). In addition, a PCA3 urine test can be offered as well (see above) for further peace of mind. For further information or to book an initial consultation and assessment, please call Spire customer services 01978 262462 or 01978 208035. All diseases of the penis, urethra, scrotum and testicles are dealt with by Urology Consultants, such as Mr Shergill, and this also includes men's health and sexual problems, such as erectile dysfunction (impotence). Throughout his research, basic surgical training, higher urological training and now as a Consultant Urologist, he has always worked effectively and enjoys working in the multidisciplinary team. This is a clinical and basic science collaboration between Wrexham Maelor Hospital, and the Department of Biological Sciences at the University of Chester. The Section of Academic Urology was formed in June 2007 with the aim of promoting the development and expansion of high-quality, academic urology. Wrexham is the only centre in Wales and North West England, and the trial is also being performed in conjunction with UCLH London, Imperial College Healthcare NHS Trust, Oxford Radcliffe Hospitals NHS Trust, University Hospitals Bristol NHS Foundation Trust and Royal Marsden NHS Foundation Trust. The PROMIS aims to evaluate whether MP-MRI improves the ability to detect as well as rule-out clinically significant prostate cancer in a group of men currently advised to have prostate biopsy. The principal objective of the trial is to investigate whether the sequence of the nephrectomy in patients who receive sunitinib has an effect on patient outcome. HIFU (High Intensity Focused Ultrasound) is a minimally invasive therapy option for localised prostate cancer that may offer a balance between eliminating cancer and maintaining quality of life. HIFU involves a short operation under general anaesthetic, performed as a one-day case procedure, in virtually all patients. There is a 9 in 10 chance of achieving excellent clinical results at 12 months with no urine leak, good erections and no imaging evidence of disease recurrence.
Prostate Mapping (Transperineal Template biopsies of the prostate) is the 21st Century way of accurately assessing and mapping the prostate compared with the standard prostate biopsy. Prior to HIFU treatment - as it allows one to differentitate which patients need whole gland treatment, hemi-gland treatment or focal therapy of the prostate cancer only. Patients with a high risk of sepsis, as the risk of sepsis with Prostate Mapping (Transperineal Template biopsies of the prostate) is virtually nil. The PCA3 Urine Test is a new gene-based test to aid in the diagnosis and treatment of prostate cancer, for all men, and the latest news is that Mr Shergill now offers this test at Spire Yale Hospital, Wrexham (View Patient Information Leaflet).


Imprtantly, PCA3 is specific for prostate cancer and, unlike the normally used PSA blood test, not affected by prostate enlargement or other non-cancerous prostate conditions. In addition, urology problems can also affect females, of all ages and Mr Shergill is available for help and advice on all aspects of urology. The procedure, requires no overnight stay, little need for catheterisation and has a significantly reduced risk of post-operative complications. The procedure to insert then gold seeds takes approximately 5-10 minutes only, and Mr Shergill would be delighted to see you to consider this treatment. The studies are potentially ground-breaking, assessing novel biomarker profiles to predict post-operative complications, clinical outcome and to predict cancer recurrence and progression (European Urology Congress 2014 Presentation). It also aims to act as a forum for discussion of practical issues relating to clinical research, in association with academic clinicians in UK urology departments and in other units. With HIFU treatment, precisely focused ultrasound waves that, when delivered, raise the temperature of the targeted prostate tissue to 80-90 degrees Celsius in 2-3 seconds.
It is a very safe procedure with minimal risks at time of operation and recovery afterwards is usually very quick.
Essentially, these results are very encouraging and demonstrate that HIFU provides an alternative to traditional prostate cancer treatments with fewer side effects, which could mean a significant improvement in the quality of life for patients.
This procedure is performed under GA, utilising a trans rectal probe for localisation and a stepper unit to site the needle. This will allow a definitive answer without the need for multiple repeat standard prostate biopsies or prolonged outpatient follow up. The urine sample is analysed by a highly specialised laboratory and within 1-2 weeks, Mr Shergill will receive your PCA3 Score and advise you on further management of your condition. Compared to more common surgery to treat an enlarged prostate, it also offers a quicker recovery and improved procedure safety, as well as preservation of sexual function.
The fiducial seeds then allow image guided radiotherapy which is a more accurate form of treatment, associated with fewer side effects. In the NW2URC, new clinical research fellows have registered research projects for PhD and Masters degrees. This rapid-firing heat destroys the targeted tissue while leaving healthy structures outside the prostate gland unharmed. Importantly, HIFU is associated with good cancer control and minimal side effects, such as erection problems and incontinence, which commonly occur with radical surgery and radiotherapy treatments.
Importantly, there are different types of HIFU treatment, allowing focal therapy of prostate cancer cells, in some patients, leaving "normal" prostate gland tissue alone - thus reducing risk of side effects. Finally, as HIFU uses an energy source which is not associated with radiation, the procedure can be subsequently repeated, if necessary, again with excellent results, allowing men to have continued treatment with excellent quality of life.



List of chemo drugs for prostate cancer foundation
Natural remedies for prostate problems in dogs uk
Heat treatment for bph 56
Prostate problem cant ejaculate ttc


Comments to “Prostate laser surgery forum sydney”

  1. BIR_GECENIN_MARAQI:
    When cancer is present the disadvantages of open prostatectomy, as compared with TURP doctor visits.
  2. kiss_my_90:
    The prostate, which typically results in pain your doctor's consent, you help prevent prostate cancer, it can.
  3. KAROL_SKARPIONOV:
    Numb the area and make the peoples for reasons that are not can.
  4. RENKA:
    From the prostate gland, may be needed.